Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion

The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor Î± (TNF-Î±) is suspected of being an important mediator of this loss. 1, 2 Evidence has been published for localised overproduction of TNF-Î± being largely responsible for the bone loss seen in rheumato...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2004-07, Vol.53 (7), p.1056-1056
Hauptverfasser:	Kast, R E, Altschuler, E L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressive Agents, Second-Generation - therapeutic use Bone density Bone Density - drug effects bupropion Bupropion - therapeutic use Crohn Disease - complications Crohn's disease Humans Letter osteoporosis Osteoporosis - etiology Psoriasis Tumor Necrosis Factor-alpha - physiology Tumor necrosis factor-TNF tumour necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1056
container_issue	7
container_start_page	1056
container_title	Gut
container_volume	53
creator	Kast, R E Altschuler, E L
description	The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor Î± (TNF-Î±) is suspected of being an important mediator of this loss. 1, 2 Evidence has been published for localised overproduction of TNF-Î± being largely responsible for the bone loss seen in rheumatoid arthritis, 3, 4 psoriatic arthritis, 5 multiple myeloma, 6 hip prosthesis loosening, 7 periodontal disease, 8 and spondyloarthropathies. 9 Anti-TNF-Î± antibody has been shown to slow the bone loss of spondyloarthropy 9 and rheumatoid arthritis. 3, 10 We have found that the commonly used antidepressant bupropion can induce remission in CD 11, 12 and have found that bupropion can lower TNF-Î± levels. 13 If bupropion is found to be effective in CD and to lower TNF-Î± levels in large trials, it might be considered for use in bone loss and osteoporosis, in CD or otherwise.
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72015366</sourcerecordid><originalsourceid>FETCH-LOGICAL-b385t-adfd2715dc6b970a894ea0c4f3a3fb8dfe16fa6c8944d1a93ee301fb91dc469c3</originalsourceid><addsrcrecordid>eNpdkc9uEzEQxleIiobCKyBLSNxWsuN_aw4IEjUUqS2XACdkedd247Brb21v1dz6GrweT4KjlAg4jEYz89Onb2aeVDNEWFPjedM8rWYQIl5TTsRp9TylLYSwaQR6Vp0iigRhjM6q74vgDdDGJ5d3oA8pAefBMoaN__XwMwHtklHJvAUx9AYEC9bXK6C8BmPIxmenemBDBGM0d_syeNDuQDuNMYyleFGdWNUn8_Ixn1VfVufr5UV9-fnjp-WHy7rFDc210lbPOaK6Y63gUDWCGAU7YrHCtm20NYhZxbrSJxopgY3BENlWIN0RJjp8Vr076I5TOxjdFStR9XKMblBxJ4Ny8t-Jdxt5E-4k4pwgBIvAm0eBGG4nk7IcXOpM3ytvwpQkn0NEMWMFfP0fuA1T9GW5vZbAcywEKtSrv_0cjfy5ewHqA-BSNvfHuYo_JOOYU3n9dSkX31bsarFYS1L49we-HbZHepPzKG-mLPfNLgwl_P4pkmLJJYKUSSTt1JdDaIt_A1ekqZY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779323991</pqid></control><display><type>article</type><title>Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kast, R E ; Altschuler, E L</creator><creatorcontrib>Kast, R E ; Altschuler, E L</creatorcontrib><description>The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor Î± (TNF-Î±) is suspected of being an important mediator of this loss. 1, 2 Evidence has been published for localised overproduction of TNF-Î± being largely responsible for the bone loss seen in rheumatoid arthritis, 3, 4 psoriatic arthritis, 5 multiple myeloma, 6 hip prosthesis loosening, 7 periodontal disease, 8 and spondyloarthropathies. 9 Anti-TNF-Î± antibody has been shown to slow the bone loss of spondyloarthropy 9 and rheumatoid arthritis. 3, 10 We have found that the commonly used antidepressant bupropion can induce remission in CD 11, 12 and have found that bupropion can lower TNF-Î± levels. 13 If bupropion is found to be effective in CD and to lower TNF-Î± levels in large trials, it might be considered for use in bone loss and osteoporosis, in CD or otherwise.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>PMID: 15194665</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Antidepressive Agents, Second-Generation - therapeutic use ; Bone density ; Bone Density - drug effects ; bupropion ; Bupropion - therapeutic use ; Crohn Disease - complications ; Crohn's disease ; Humans ; Letter ; osteoporosis ; Osteoporosis - etiology ; Psoriasis ; Tumor Necrosis Factor-alpha - physiology ; Tumor necrosis factor-TNF ; tumour necrosis factor</subject><ispartof>Gut, 2004-07, Vol.53 (7), p.1056-1056</ispartof><rights>Copyright 2004 by Gut</rights><rights>Copyright: 2004 Copyright 2004 by Gut</rights><rights>Copyright © Copyright 2004 by Gut 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774110/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774110/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15194665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kast, R E</creatorcontrib><creatorcontrib>Altschuler, E L</creatorcontrib><title>Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion</title><title>Gut</title><addtitle>Gut</addtitle><description>The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor Î± (TNF-Î±) is suspected of being an important mediator of this loss. 1, 2 Evidence has been published for localised overproduction of TNF-Î± being largely responsible for the bone loss seen in rheumatoid arthritis, 3, 4 psoriatic arthritis, 5 multiple myeloma, 6 hip prosthesis loosening, 7 periodontal disease, 8 and spondyloarthropathies. 9 Anti-TNF-Î± antibody has been shown to slow the bone loss of spondyloarthropy 9 and rheumatoid arthritis. 3, 10 We have found that the commonly used antidepressant bupropion can induce remission in CD 11, 12 and have found that bupropion can lower TNF-Î± levels. 13 If bupropion is found to be effective in CD and to lower TNF-Î± levels in large trials, it might be considered for use in bone loss and osteoporosis, in CD or otherwise.</description><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>bupropion</subject><subject>Bupropion - therapeutic use</subject><subject>Crohn Disease - complications</subject><subject>Crohn's disease</subject><subject>Humans</subject><subject>Letter</subject><subject>osteoporosis</subject><subject>Osteoporosis - etiology</subject><subject>Psoriasis</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><subject>Tumor necrosis factor-TNF</subject><subject>tumour necrosis factor</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkc9uEzEQxleIiobCKyBLSNxWsuN_aw4IEjUUqS2XACdkedd247Brb21v1dz6GrweT4KjlAg4jEYz89Onb2aeVDNEWFPjedM8rWYQIl5TTsRp9TylLYSwaQR6Vp0iigRhjM6q74vgDdDGJ5d3oA8pAefBMoaN__XwMwHtklHJvAUx9AYEC9bXK6C8BmPIxmenemBDBGM0d_syeNDuQDuNMYyleFGdWNUn8_Ixn1VfVufr5UV9-fnjp-WHy7rFDc210lbPOaK6Y63gUDWCGAU7YrHCtm20NYhZxbrSJxopgY3BENlWIN0RJjp8Vr076I5TOxjdFStR9XKMblBxJ4Ny8t-Jdxt5E-4k4pwgBIvAm0eBGG4nk7IcXOpM3ytvwpQkn0NEMWMFfP0fuA1T9GW5vZbAcywEKtSrv_0cjfy5ewHqA-BSNvfHuYo_JOOYU3n9dSkX31bsarFYS1L49we-HbZHepPzKG-mLPfNLgwl_P4pkmLJJYKUSSTt1JdDaIt_A1ekqZY</recordid><startdate>200407</startdate><enddate>200407</enddate><creator>Kast, R E</creator><creator>Altschuler, E L</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ Publishing Group LTD</general><general>Copyright 2004 by Gut</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200407</creationdate><title>Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion</title><author>Kast, R E ; Altschuler, E L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b385t-adfd2715dc6b970a894ea0c4f3a3fb8dfe16fa6c8944d1a93ee301fb91dc469c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>bupropion</topic><topic>Bupropion - therapeutic use</topic><topic>Crohn Disease - complications</topic><topic>Crohn's disease</topic><topic>Humans</topic><topic>Letter</topic><topic>osteoporosis</topic><topic>Osteoporosis - etiology</topic><topic>Psoriasis</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><topic>Tumor necrosis factor-TNF</topic><topic>tumour necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kast, R E</creatorcontrib><creatorcontrib>Altschuler, E L</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kast, R E</au><au>Altschuler, E L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2004-07</date><risdate>2004</risdate><volume>53</volume><issue>7</issue><spage>1056</spage><epage>1056</epage><pages>1056-1056</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>The subject of bone mineral density loss in CD has been recently reviewed; tumour necrosis factor Î± (TNF-Î±) is suspected of being an important mediator of this loss. 1, 2 Evidence has been published for localised overproduction of TNF-Î± being largely responsible for the bone loss seen in rheumatoid arthritis, 3, 4 psoriatic arthritis, 5 multiple myeloma, 6 hip prosthesis loosening, 7 periodontal disease, 8 and spondyloarthropathies. 9 Anti-TNF-Î± antibody has been shown to slow the bone loss of spondyloarthropy 9 and rheumatoid arthritis. 3, 10 We have found that the commonly used antidepressant bupropion can induce remission in CD 11, 12 and have found that bupropion can lower TNF-Î± levels. 13 If bupropion is found to be effective in CD and to lower TNF-Î± levels in large trials, it might be considered for use in bone loss and osteoporosis, in CD or otherwise.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>15194665</pmid><tpages>1</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0017-5749
ispartof	Gut, 2004-07, Vol.53 (7), p.1056-1056
issn	0017-5749 1468-3288 1458-3288
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774110
source	MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects	Antidepressive Agents, Second-Generation - therapeutic use Bone density Bone Density - drug effects bupropion Bupropion - therapeutic use Crohn Disease - complications Crohn's disease Humans Letter osteoporosis Osteoporosis - etiology Psoriasis Tumor Necrosis Factor-alpha - physiology Tumor necrosis factor-TNF tumour necrosis factor
title	Bone density loss in Crohn’s disease: role of TNF and potential for prevention by bupropion
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A20%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20density%20loss%20in%20Crohn%E2%80%99s%20disease:%20role%20of%20TNF%20and%20potential%20for%20prevention%20by%20bupropion&rft.jtitle=Gut&rft.au=Kast,%20R%20E&rft.date=2004-07&rft.volume=53&rft.issue=7&rft.spage=1056&rft.epage=1056&rft.pages=1056-1056&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72015366%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779323991&rft_id=info:pmid/15194665&rfr_iscdi=true